Standout Papers

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-H... 1984 2026 1998 2012 1.5k
  1. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds (1988)
    Rudi Pauwels, Jan Balzarini et al. Journal of Virological Methods
  2. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin (1984)
    Diane Pennica, Glenn E. Nedwin et al. Nature
  3. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) (2020)
    Guangdi Li, Erik De Clercq Nature Reviews Drug Discovery
  4. Approved Antiviral Drugs over the Past 50 Years (2016)
    Erik De Clercq, Guangdi Li Clinical Microbiology Reviews
  5. CXCR4-activated astrocyte glutamate release via TNFα: amplification by microglia triggers neurotoxicity (2001)
    Paola Bezzi, Marı́a Domercq et al. Nature Neuroscience
  6. Human transforming growth factor-α: Precursor structure and expression in E. coli (1984)
    Erik De Clercq, Anita B. Roberts et al. Cell
  7. Antiviral drugs in current clinical use (2004)
    Erik De Clercq Journal of Clinical Virology
  8. 1,2,3-Triazole-[2,5-Bis-O-(tert-butyldimethylsilyl)-.beta.-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) (TSAO) Analogs: Synthesis and Anti-HIV-1 Activity (1994)
    Rosa Álvarez, Sonsoles Velázquez et al. Journal of Medicinal Chemistry
  9. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives (1990)
    Rudi Pauwels, Koen Andries et al. Nature
  10. A novel selective broad-spectrum anti-DNA virus agent (1986)
    Erik De Clercq, Antonı́n Holý et al. Nature
  11. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor (1998)
    Dominique Schols, Steven Lin et al. Nature Medicine
  12. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections (1995)
    Erik De Clercq Journal of Medicinal Chemistry
  13. Expression of human immune interferon cDNA in E. coli and monkey cells (1982)
    Patrick W. Gray, David W. M. Leung et al. Nature
  14. Angiogenesis: regulators and clinical applications (2001)
    Sandra Liekens, Erik De Clercq et al. Biochemical Pharmacology
  15. Antiviral agents active against influenza A viruses (2006)
    Erik De Clercq Nature Reviews Drug Discovery
  16. Comparative Efficacy of Antiherpes Drugs against Different Strains of Herpes Simplex Virus (1980)
    Erik De Clercq, J Descamps et al. The Journal of Infectious Diseases
  17. Acyclic nucleoside phosphonates: a key class of antiviral drugs (2005)
    Erik De Clercq, Antonı́n Holý Nature Reviews Drug Discovery
  18. HIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells (2002)
    Peter Cherepanov, Goedele N. Maertens et al. Journal of Biological Chemistry
  19. Strategies in the design of antiviral drugs (2002)
    Erik De Clercq Nature Reviews Drug Discovery
  20. Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4′-chlorophenyl)thiazol-2-yl] thiosemicarbazide (1999)
    S. N. Pandeya, Dharmarajan Sriram et al. European Journal of Pharmaceutical Sciences
  21. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV (2008)
    Erik De Clercq International Journal of Antimicrobial Agents
  22. (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. (1979)
    Erik De Clercq, J Descamps et al. Proceedings of the National Academy of Sciences
  23. Therapeutic strategies for COVID-19: progress and lessons learned (2023)
    Guangdi Li, Rolf Hilgenfeld et al. Nature Reviews Drug Discovery

Immediate Impact

20 by Nobel laureates 73 from Science/Nature 106 standout
Sub-graph 1 of 17

Citing Papers

The Chemistry and Applications of Metal-Organic Frameworks
2013 StandoutScienceNobel
Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection
2013 StandoutNature
12 intermediate papers

Works of Erik De Clercq being referenced

In Vivo Evolution of Human Immunodeficiency Virus Type 1 toward Increased Pathogenicity through CXCR4-Mediated Killing of Uninfected CD4 T Cells
2003
Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100
1998
and 18 more

Author Peers

Author Last Decade Papers Cites
Erik De Clercq 43499 30815 33640 38192 2.8k 116.8k
Ian A. Wilson 12476 18418 5136 34918 756 74.3k
Robert C. Gallo 18284 13204 1502 18552 693 76.1k
Jan Balzarini 14419 8162 12045 10681 869 32.9k
David Baltimore 11005 11338 1330 75494 701 140.0k
Guido Kroemer 5143 46872 4406 125595 1.3k 229.0k
Shizuo Akira 23610 47817 1355 78422 1.2k 256.9k
Anthony S. Fauci 24594 20019 561 10893 784 93.6k
Douglas D. Richman 37026 12883 981 7020 506 55.1k
Yves Pommier 6085 2306 9435 47489 860 61.0k
Richard A. Flavell 11795 19405 1149 74744 1.2k 176.5k

All Works

Loading papers...

Rankless by CCL
2026